[an error occurred while processing this directive] ����Ƥ���Բ�ѧ��־ 2007, 33(6) 331-333 DOI:     ISSN: 2096-5540 CN: 32-1880/R

����Ŀ¼ | ����Ŀ¼ | ������� | �߼�����                                                            [��ӡ��ҳ]   [�ر�]
����
��չ����
������Ϣ
Supporting info
PDFȫ��
[HTMLȫ��]
�����
�����뷴��
�ѱ����Ƽ�������
�����ҵ����
�������ù�����
����
Email Alert
���·���
���������Ϣ
���Ĺؼ����������
���崯,���Լ�����
����
���������������
¥����
��ɽ�
PubMed
Article by LOU Jun-xiao
Article by ZHU Ke-jian

�������������崯�����ƽ�չ

¥����, ��ɽ�

�㽭��ѧҽѧԺ�������ݷ�ҽԺƤ����, 310016

ժҪ��

�������������崯��һ���ټ��ij�Ⱦɫ�������Ŵ��Լ���,��ATP2C1����ͻ�����¡��ٴ��ϲ��鷴��,��������,Ŀǰ��Ҫ��ҩ�����ơ�������ƺͼ������ơ�ҩ�����ư�����Ƥ�ʼ��ء������ء�άA���ࡢά����D3���������Ī˾���ⶾ���صȡ�Ϊ��ֹ�������ӳ�����ʱ��,��ѡ��������ƺͼ������ơ����׽���-6���������ѧ��Ч�������Ʊ�����

�ؼ����� ���崯,���Լ�����   ����  

Advances in the treatment of benign familial pemphigus

Department of Dermatology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China

Department of Dermatology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China

Abstract:

Benign familial pemphigus (HHD) is a rare autosomal dominant disease caused by mutations in the ATP2C1gene encoding a novel Ca2+ pump. It is a refractory skin disease with recurrent characteristic lesions. At present, its therapeutic options include medications, surgical intervention and laser therapy. Corticosteroids, antibiotics, retinoids, vitamin D3 analogues, tacrolimus and botulinal toxin are commonly used in its treatment. In order to prolong remission and prevent relapse, surgical intervention and laser therapy are recommended. Biological therapy, such as anti IL-6 antibody, has a good prospect in the treatment of HHD.

Keywords: Pemphigus, benign familial   Therapy  
�ո����� 2007-04-11 �޻�����  ����淢������  
DOI:
������Ŀ:

ͨѶ����: ��ɽ�, email:zhukejiansrrsh@126.com
���߼��:

�ο����ף�
[1] Hu Z,Bonifas JM,Beech J,et al.Mutations in ATP2C1,encoding a calcium pump,cause Hailey-Hailey disease.Nat Genet,2000,24(1):61-65.
[2] Ikeda S,Suga Y,Ogawa H.Successful management of Hailey-Hailey disease with potent topical steroid ointment.J Dermatol Sci,1993,5(3):205-211.
[3] Brinkmeier T,Frosch PJ.Oral antibiotics with antiinflammatory/immunomodulatory effects in the treatment of various dermatoses.Hautarzt,2002,53(7):456-465.
[4] Nasea MR,De Pasquale R,Amodeo R,et al.Treatment of Hailey-Hailey disease with oral erythromycin.J Dermatologica Treatment,2000,11(4):273-277.
[5] Kellermayer R,Szigeti R,Keeling KM,et al.Aminoglycosides as potential pharmacogenetic agents in the treatment of Hailey-Hailey disease.J Invest Dermatol,2006,126(1):229-231.
[6] Hunt MJ,Salisbury EL Pajnter DM,et al.Vesiculobullous Hailey-Hailey disease:successful treatment with oral retinoids.Australas J Dermatol,1996,37(4):196-198.
[7] Mashiko M,Akiyama M,Tsuji-Abe Y,et al.Bacteria 1 infection-induced generalized Hailey-Hailey disease successfully treated by etretinate.Clin Exp Dermatol,2006,31(1):57-59.
[8] Aoki T,Hashimoto H,Koseki S,et al.1alpha,24-dihydroxyvitamin D3(tacalcito1)is effective against Hailey-Hailey disease both in vivo and in vitro.Br J Dermatol,1998,139(5):897-901.
[9] Rajpara SM,King CM.Hailey-Hailey disease responsive to topiral calcitriol.Br J Dermatol,2005,152(4):816-817.
[10] Rocha Paris F,Fidalgo A,Baptism J,et al.Topical tacrolimus in Hailey-Hailey disease.Int J Tissue React,2005,27(4):151-154.
[11] Sand C,Thomsen HK.Topical tacrolimus ointment is an effective therapy for Hailey-Hailey disease.Arch Dermatol,2003,139(11):1401-1402.
[12] Laffitte E,Panizzon RG.Is topical taerolimus really an effective therapy for Hailey-Hailey disease? Arch Dermatol,2004,140(10):1282.
[13] Lapiere JC,Hirsh A,Gordon KB,et al.Botulinum toxin type A for the treatment of axillary Hailey-Hailey disease.Dermtol Surg,2000,26(4):371-374.
[14] Konrad H,Karamfilov T,Wollina U.Intraeutaneous botulinum toxin A versus ablative therapy of Hailey-Hailey disease-a case report.J Cosmet Laser Ther,2001,3(4):181-184.
[15] Christian MM,Moy RL.Treatment of Hailey-Hailey disease(orbenign familial pemphigus)using short pulsed and short dwell time carbon dioxide lasers.Dermatol Surg,1999,25(8):661-663.
[16] Collet Villette AM,Richard MA,Fourquet F,et al.Treatment of Hailey-Hailey disease with carbon dioxide laser vaporization.Ann Dermatol Venereol,2005,132(8-9 Pt 1):637-640.
[17] Beier C,Kaufmann R.Efficacy of erbium:YAG laser ablation in Darier disense and Hailey-Hailey disease.Arch Dermatol,1999,135(4):423-427.
[18] Fisher GH,Geronemus RG.Improvement of familial benign pemphigus after treatment with pulsed-dye laser:a case report.Dermatol Surg,2006,32(7):966-968.
[19] Ruiz-Rodriguez R Alvarez JG,Jaen P,et al.Photodynamic therapy with 5-aminolevulinic acid for recalcitrant familial be-nign pemphigas(Hailey-Hailey disease).J Am Acad Dermatol,2002,47(5):740-742.
[20] Mayuzumi N,Ikeda S,Kawada H,et al.Effects of ultraviolet Birradiation,proinflammatory cytokines and raised extracellular calcium concentration on the expression of ATP2A2 and ATP2C1.Br J Dermatol,2005,152(4):697-701.
[21] Mayuzumi N,Ikeda S,Kawada H,et al.Effects of drugs and anticytokine antibodies on expression of ATP2A2 and ATP2C1 in eultttred normal human keratinoeytes.Br J Dermatol,2005,152(5):920-924.
�������������
1�������,������.�������������崯[J]. ����Ƥ���Բ�ѧ��־, 2008,34(6): 388-390
2��������, �Ÿ���.�������������崯��������ѧ�о��½�չ[J]. ����Ƥ���Բ�ѧ��־, 0,(): 370-372
3��������, �Ÿ���.�������������崯��������ѧ�о��½�չ[J]. ����Ƥ���Բ�ѧ��־, 0,(): 370-372
4��¥����, ��ɽ�.�������������崯�����ƽ�չ[J]. ����Ƥ���Բ�ѧ��־, 0,(): 331-333
5��������, �Ÿ���.�������������崯��������ѧ�о��½�չ[J]. ����Ƥ���Բ�ѧ��־, 2005,31(6): 370-372

�������� (��ע��:��վʵ�������Ը�, �벻Ҫ������ѧ���޹ص�����!�������ݲ�����վ�۵�.)

Copyright 2008 by ����Ƥ���Բ�ѧ��־